PMID- 32982425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Long Noncoding RNA SNHG7 Accelerates Proliferation, Migration and Invasion of 
      Non-Small Cell Lung Cancer Cells by Suppressing miR-181a-5p Through AKT/mTOR 
      Signaling Pathway.
PG  - 8303-8312
LID - 10.2147/CMAR.S258487 [doi]
AB  - PURPOSE: Non-small cell lung cancer (NSCLC) is a typical epithelial lung cancer 
      with high metastasis, incidence and mortality. In recent years, long noncoding 
      RNA small nucleolar RNA host gene 7 (SNHG7) has been identified as significant 
      regulator in different cancer types, including NSCLC. However, the underlying 
      molecular mechanism of SNHG7 during NSCLC tumorigenesis and progression remains 
      largely unclear. METHODS: SNHG7 and miR-181a-5p expression in NSCLC tumors and 
      cells were detected by qRT-PCR. Cell viability, migration, invasion and apoptosis 
      were evaluated by CCK-8, transwell and flow cytometry assay, respectively. A549 
      and NCI-H1299 xenograft mice model was constructed by subcutaneously injecting 
      cells stably transfected with sh-SNHG7 and sh-NC. The interaction between SNHG7 
      and miR-181a-5p was validated by luciferase reporter system, RIP and RNA pull 
      down assay. Protein expression of cleaved caspase 3, proliferating cell nuclear 
      antigen (PCNA), AKT, p-AKT, mammalian target of rapamycin (mTOR) and p-mTOR was 
      analyzed by Western blot. RESULTS: SNHG7 expression was up-regulated while 
      miR-181a-5p expression was down-regulated in NSCLC tumors, especially those from 
      patients at Phase III+IV, compared with normal tissues. However, SNHG7 depletion 
      attenuated tumor growth in vitro and in vivo. Moreover, miR-181a-5p inhibitor 
      abolished SNHG7 silencing induced inhibition on proliferation, migration and 
      invasion in NSCLC. Subsequently, we found SNHG7 modulated cell progression by 
      targeting miR-181a-5p and activating AKT/mTOR signaling pathway. CONCLUSION: 
      SNHG7 accelerates proliferation, migration and invasion of NSCLC by suppressing 
      miR-181a-5p through AKT/mTOR signaling pathway, thus presenting desirable 
      biomarkers for NSCLC therapy.
CI  - (c) 2020 Li et al.
FAU - Li, Liping
AU  - Li L
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Ye, Dan
AU  - Ye D
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Liu, Liang
AU  - Liu L
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Li, Xiaoju
AU  - Li X
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Su, Shengtian
AU  - Su S
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Lu, Wenjing
AU  - Lu W
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
FAU - Yu, Zhigao
AU  - Yu Z
AD  - Department of Oncology, Xiantao First People's Hospital, Xiantao, Hubei, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7494385
OTO - NOTNLM
OT  - AKT/mTOR pathway
OT  - NSCLC
OT  - SNHG7
OT  - miR-181a-5p
OT  - progression
COIS- The authors declare that they have no conflicts of interest in this work.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
PMCR- 2020/09/10
CRDT- 2020/09/28 05:37
PHST- 2020/04/16 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
PHST- 2020/09/10 00:00 [pmc-release]
AID - 258487 [pii]
AID - 10.2147/CMAR.S258487 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Sep 10;12:8303-8312. doi: 10.2147/CMAR.S258487. 
      eCollection 2020.